argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx SE

UBS analyst Xian Deng maintained a Hold rating on arGEN X yesterday. The company’s shares closed last Tuesday at €645.80. According to TipRanks, De...

arGEN X (0QW0) Gets a Hold from UBS

Wells Fargo analyst Derek Archila maintained a Buy rating on Argenx Se today and set a price target of $1,247.00. According to TipRanks, Archila is...

Argenx Se (ARGX) Gets a Buy from Wells Fargo

An announcement from Argenx Se ( ($ARGX) ) is now available. Argenx SE, the Euronext and Nasdaq-listed immunology specialist, has called its Annual...

Argenx Sets May 6, 2026 AGM and Unveils Board Changes as Jim Daly Retires

In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Argenx Se, with a price target of $1,000.00. Nierengarten co...

Argenx Se (ARGX) Gets a Buy from Wedbush

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NeurAxis, Inc. (NRXS – Research Report), Argenx Se (...

Analysts Offer Insights on Healthcare Companies: NeurAxis, Inc. (NRXS), Argenx Se (ARGX) and Teladoc (TDOC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Apellis Pharmaceuticals (APLS – Research Report) and...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARGX	$782.20	+2.19%	252.40K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARGX	$782.20	+2.2%	252.40K
3
4
5
6

ARGX

ARGX

Get argenx SE Data in Excel

Get argenx SE Data in Excel